Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • CCI approves Bayer's...

    CCI approves Bayer's acquisition of Monsanto

    Written by Ruby Khatun Khatun Published On 2018-05-23T09:15:56+05:30  |  Updated On 23 May 2018 9:15 AM IST
    CCI approves Bayers acquisition of Monsanto

    New Delhi: India’s competition watchdog has approved Bayer’s proposed $66-billion acquisition of US biotech firm Monsanto, subject to modifications.


    The approval comes as Monsanto faces opposition in India over the promotion of genetically modified crops and issues of royalty and patents.


    Competition Commission of India tweeted on Tuesday that it cleared the “acquisition of Monsanto by Bayer AG, subject to compliance of certain modifications.” The deal was announced in September 2016.


    The CCI had launched a public consultation process in January to determine whether the merger between the global giants to create the world’s largest seed and pesticide company would have any adverse impact on competition in the country.


    India is among the 30 countries where approval is needed for the merger of the worldwide operations of the two companies.


    The major approvals still required are from the US Department of Justice and the regulators in Canada and Mexico.


    Bayer said in a statement that the CCI has conditionally approved its proposed acquisition of Monsanto.


    “Obtaining clearance from the CCI is another milestone towards the global acquisition of Monsanto. The combination brings together two different, but highly complementary businesses,” Bayer said in a statement.


    The German company said its combination with Monsanto will create a global leader in agriculture with a broad portfolio, providing superior product offerings and tailor-made solutions to farmers across all crops in all regions.


    The Bayer group has been present in India since 1896 and it has two divisions — crop science and pharmaceuticals.


    The group has one listed entity in India — Bayer CropScience.

    AcquisitionApprovesBayerCCICompetition Commission of IndiamergerMonsantopatents
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok